(J Assist Reprod Genet[TA])
6,486 results
  • Factors associated with cannabis use among infertile patients and their partner. [Journal Article]
    J Assist Reprod Genet. 2026 Oct 31. [Online ahead of print]Steckler A, Kruzan M, … Sauerbrun-Cutler MTJA
  • CONCLUSIONS: Cannabis use increased over the study period and clustered with other behavioral and psychosocial factors. Younger, non-married individuals and those reporting tobacco use or anxiety/depression may benefit from targeted cannabis screening and preconception counseling.
  • Expanded Carrier Screening in gamete donation identifies clinically relevant donor-recipient genetic incompatibilities. [Journal Article]
    J Assist Reprod Genet. 2026 Oct 29. [Online ahead of print]Fucci R, Iserani A, … Coccia MEJA
  • CONCLUSIONS: ECS identified a substantial proportion of donor-recipient shared carrier findings. However, the clinical relevance and incremental contribution of ECS beyond standard donor screening depend on the specific condition and the genes and variants already assessed in the donor. These findings support the use of ECS as a broader approach to reproductive risk assessment, while highlighting the need for gene-level matching data to quantify its incremental clinical utility.
  • Artificial oocyte activation in patients with fertilization failure using calcium ionophores: a meta-analysis on reproductive outcomes. [Journal Article]
    J Assist Reprod Genet. 2026 Oct 28. [Online ahead of print]de Celis C, Gil J, … de Los Santos MJJA
  • CONCLUSIONS: Calcium ionophore-mediated activation may enhance reproductive outcomes in ICSI cycles in patients with fertilization failure, without increasing miscarriage or adverse neonatal outcomes. Their selective use could prevent cycle cancellation and reduce the emotional and financial burden associated with repeated ICSI failures. However, given the variability in ionophore protocols and experimental design, further randomized studies are warranted to standardize dosing, timing, and indications before universal clinical adoption.
  • Waived semen analyzers in clinical practice: analytical standards, regulatory categorization, and the limits of automated assessment. [Letter]
    J Assist Reprod Genet. 2026 Oct 26. [Online ahead of print]McCulloh DH, Boldt J, … Curchoe CLJA
  • CONCLUSIONS: Waived semen analyzers offer genuine advantages in workflow efficiency and intra-instrument reproducibility and are appropriate for preliminary assessment of major male factor causes of infertility. Documented limitations in morphology accuracy near the 4% Tygerberg threshold, motility detection at low values, and handling of complex samples make them insufficient as stand-alone replacements for qualified manual analysis in high-stakes contexts including azoospermia determination and pharmacologic research as well as studies on infertility pathophysiology and diagnosis, and fertility prognosis. The scope of the CLIA waivers is settled; the applicable CPT billing codes remain unresolved and require professional society engagement with the American Medical Association's (AMA's) CPT Editorial Panel. Laboratory validation is a professional obligation regardless of CLIA complexity level and is also required internationally by ISO 15189.
  • 150 years after Hertwig: how the discovery of fertilisation transformed reproductive medicine. [Review]
    J Assist Reprod Genet. 2026 Oct 25. [Online ahead of print]Viville SJA
  • The year 2026 marks the 150th anniversary of Oscar Hertwig's demonstration that fertilisation results from the fusion of sperm and oocyte, a discovery that fundamentally transformed biology and medicine. This historical review retraces the intellectual journey from ancient philosophical and theological interpretations of conception through the theories of spontaneous generation, preformationism, …
  • X-linked novel hemizygous ADGRG2 variants associated with male factor infertility. [Journal Article]
    J Assist Reprod Genet. 2026 Oct 19. [Online ahead of print]Yuan Y, Li Y, … Tu CJA
  • CONCLUSIONS: Our findings established ADGRG2 variants cause male infertility and may be the etiology of CBAVD, expanding the associated mutational spectrum and reinforcing the gene's critical role in male fertility, thereby supporting the integration of comprehensive ADGRG2 screening into clinical practice to enhance genetic and reproductive counseling for affected patients.